Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-745-1700
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.61 million
Profitability
Miscellaneous
Employees86
Next Earnings Date8/6/2019 (Estimated)
OptionableOptionable
Ardelyx (NASDAQ:ARDX) Frequently Asked Questions
What is Ardelyx's stock symbol?
Ardelyx trades on the NASDAQ under the ticker symbol "ARDX."
How were Ardelyx's earnings last quarter?
Ardelyx Inc (NASDAQ:ARDX) announced its quarterly earnings results on Tuesday, May, 7th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.39) by $0.03. View Ardelyx's Earnings History.
When is Ardelyx's next earnings date?
What price target have analysts set for ARDX?
3 Wall Street analysts have issued twelve-month target prices for Ardelyx's stock. Their predictions range from $7.00 to $15.00. On average, they expect Ardelyx's share price to reach $11.00 in the next year. This suggests a possible upside of 291.5% from the stock's current price. View Analyst Price Targets for Ardelyx.
What is the consensus analysts' recommendation for Ardelyx?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ardelyx.
Has Ardelyx been receiving favorable news coverage?
News stories about ARDX stock have been trending somewhat negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ardelyx earned a daily sentiment score of -1.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Ardelyx's key competitors?
Some companies that are related to Ardelyx include ZIOPHARM Oncology (ZIOP), Emisphere Technologies (EMIS), ChemoCentryx (CCXI), Vectura Group (VEGPF), ZEALAND PHARMA/S (ZEAL), Kura Oncology (KURA), Stemline Therapeutics (STML), Advanz Pharma (CXRXF), TG Therapeutics (TGTX), Organogenesis (ORGO), Lexicon Pharmaceuticals (LXRX), Crinetics Pharmaceuticals (CRNX), Aurinia Pharmaceuticals (AUPH), Akebia Therapeutics (AKBA) and Viking Therapeutics (VKTX).
What other stocks do shareholders of Ardelyx own?
Who are Ardelyx's key executives?
Ardelyx's management team includes the folowing people:
- Mr. Michael G. Raab, Pres, CEO & Director (Age 54)
- Mr. David Rosenbaum, Chief Devel. Officer (Age 58)
- Mr. Mark E. Kaufmann, CFO & Treasurer (Age 51)
- Mr. Jeffrey W. Jacobs, Sr. VP of Technical Operations (Age 56)
- Mr. Bryan Shaw, Chief Accounting Officer, VP and Controller (Age 65)
Who are Ardelyx's major shareholders?
Ardelyx's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.40%), Renaissance Technologies LLC (3.17%), Dimensional Fund Advisors LP (2.83%), Oxford Asset Management LLP (0.60%), Wedbush Securities Inc. (0.31%) and Charles Schwab Investment Management Inc. (0.26%). Company insiders that own Ardelyx stock include David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Gordon Ringold, Mark Kaufmann, Michael Raab, Reginald Seeto and Scott D Sandell. View Institutional Ownership Trends for Ardelyx.
Which major investors are selling Ardelyx stock?
ARDX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Morgan Stanley, Algert Global LLC, Charles Schwab Investment Management Inc., Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Connor Clark & Lunn Investment Management Ltd. and Man Group plc. Company insiders that have sold Ardelyx company stock in the last year include David P Rosenbaum, Elizabeth A Grammer, Mark Kaufmann, Michael Raab and Scott D Sandell. View Insider Buying and Selling for Ardelyx.
Which major investors are buying Ardelyx stock?
ARDX stock was bought by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, BlackRock Inc., Wedbush Securities Inc., Acadian Asset Management LLC, ClariVest Asset Management LLC, Bailard Inc., PNC Financial Services Group Inc. and Parametric Portfolio Associates LLC. View Insider Buying and Selling for Ardelyx.
How do I buy shares of Ardelyx?
Shares of ARDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ardelyx's stock price today?
One share of ARDX stock can currently be purchased for approximately $2.81.
How big of a company is Ardelyx?
Ardelyx has a market capitalization of $175.91 million and generates $2.61 million in revenue each year. The biopharmaceutical company earns $-91,300,000.00 in net income (profit) each year or ($1.62) on an earnings per share basis. Ardelyx employs 86 workers across the globe.
What is Ardelyx's official website?
How can I contact Ardelyx?
Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The biopharmaceutical company can be reached via phone at 510-745-1700 or via email at [email protected]
MarketBeat Community Rating for Ardelyx (NASDAQ ARDX)
MarketBeat's community ratings are surveys of what our community members think about Ardelyx and other stocks. Vote "Outperform" if you believe ARDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
